Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ALT Clear all
Terminated Phase 1 Interventional

Study of Fish Oil to Reduce ALT Levels in Adolescents

NCT00694746
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions
Omega-3-acid ethyl esters, Placebo
Drug
Lead sponsor
Boston University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

NCT01154985
View directory record Official record
Conditions
Steatohepatitis
Interventions
Placebo capsule, EPA-E 300 mg capsule
Drug
Lead sponsor
Mochida Pharmaceutical Company, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jul 22, 2026, 12:16 PM EDT
Active, not recruiting Not applicable Interventional

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

NCT05686317
View directory record Official record
Conditions
Heart Failure
Interventions
Edwards APTURE transcatheter shunt system, Sham procedure
Device · Diagnostic Test
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 12:16 PM EDT
Completed No phase listed Observational

Leg Function and ADL After ALT Reconstruction for Head and Neck Cancer

NCT02332161
View directory record Official record
Conditions
Free Tissue Flaps, Head and Neck Neoplasms
Interventions
surveys, evaluative tests for leg function
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 4 Interventional Results available

Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery

NCT00656292
View directory record Official record
Conditions
Perioperative Inflammatory Response
Interventions
Simvastatin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Not applicable Interventional

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

NCT00046267
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Diabetes Mellitus
Interventions
Niacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Jul 22, 2026, 12:16 PM EDT
Terminated Phase 4 Interventional Results available

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

NCT02253394
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan plus Spironolactone, Ambrisentan plus Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jul 22, 2026, 12:16 PM EDT
Not listed No phase listed Observational

ALT Routinely Recorded Remotely: A Comparator Study of Liver Function Tests Using the Tasso+ to Venipuncture.

NCT05259618
View directory record Official record
Conditions
Elevated Alanine Transaminase (ALT)
Interventions
Tasso+ SST
Other
Lead sponsor
Tasso Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Aurora, Colorado • New York, New York • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jul 22, 2026, 12:16 PM EDT
Active, not recruiting Not applicable Interventional

Early Feasibility Study - Edwards APTURE Transcatheter Shunt System

NCT03523416
View directory record Official record
Conditions
Heart Failure
Interventions
Transcatheter Atrial Shunt System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Arista for ALT Donor Sites to Reduce Drain Output

NCT02477774
View directory record Official record
Conditions
Seroma
Interventions
ARISTA
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

NCT00507507
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, FTC, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Jul 22, 2026, 12:16 PM EDT
Completed No phase listed Observational

Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

NCT00890448
View directory record Official record
Conditions
Toxicity
Interventions
Pharmacogenomic whole blood sampling
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Jacksonville, Florida • Jupiter, Florida • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 2 Interventional

Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)

NCT01539343
View directory record Official record
Conditions
Infection
Interventions
Antimicrobial Solution
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jul 22, 2026, 12:16 PM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aminotransferase Trends During Prolonged Acetaminophen Dosing

NCT00743093
View directory record Official record
Conditions
Drug Toxicity, Healthy
Interventions
acetaminophen, placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Jul 22, 2026, 12:16 PM EDT
Not listed Not applicable Interventional

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

NCT03073343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
Interventions
Betaine (trimethyglycine)
Dietary Supplement
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 12:16 PM EDT
Terminated Phase 2 Interventional Results available

Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204
View directory record Official record
Conditions
Diabetes Complications, Fatty Liver
Interventions
exenatide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 22, 2026, 12:16 PM EDT
Recruiting Phase 2 Interventional

LGG Supplementation in Patients With AUD and ALD

NCT05178069
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol-associated Liver Disease
Interventions
: Placebo for Probiotic, Lactobacillus Rhamnosus GG
Drug · Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 22, 2026, 12:16 PM EDT
Withdrawn Not applicable Interventional

A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)

NCT03163810
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Erchonia Verju Laser, Erchonia EVRL Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jul 22, 2026, 12:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

NCT01808352
View directory record Official record
Conditions
HIV
Interventions
Observational
Other
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older · Male only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Jul 22, 2026, 12:16 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Cardiox Liver Function Test Pivotal Trial

NCT02552901
View directory record Official record
Conditions
Hepatic Failure, Liver Failure
Interventions
0.1 mg/kg ICG Dose, 0.5 mg/kg ICG dose
Drug
Lead sponsor
Cardiox Corporation
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 2 Interventional

Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies

NCT02556372
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
JKB-122
Drug
Lead sponsor
TaiwanJ Pharmaceuticals Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 22, 2026, 12:16 PM EDT
Completed Phase 2 Interventional

Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease

NCT00491543
View directory record Official record
Conditions
Diabetes, Coronary Artery Disease
Interventions
ALT-2074
Drug
Lead sponsor
Synvista Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2008 · Synced Jul 22, 2026, 12:16 PM EDT